Johnson & Johnson (JNJ)
Pressure builds on J&J to halt global talc sales (NYSE:JNJ)
More than 170 nonprofit groups are calling on Johnson & Johnson (NYSE:JNJ) to stop selling its talc-based baby powder worldwide after the company said in M
Potential COVID-19 vaccine not 'single solution' to pandemic, Johnson & Johnson CEO says
U.S. drugmaker Johnson & Johnson aims to begin clinical testing of its COVID-19 vaccine in the coming weeks and produce billions of doses in 2021, chief executive officer Alex Gorsky said on Wednesday, but cautioned that it will take more than one vaccine to rein in the virus.
The CEO of a tiny biotech working on a coronavirus vaccine tells us how a $1.6 billion grant from the US government will 'level the playing field' with Big Pharma (NVAX)
A tiny biotech called Novavax has secured the largest deal yet from the US government to support its coronavirus vaccine program. Novavax landed a $1.6 billion funding deal that will help test its vaccine candidate in large clinical trials and ramp up manufacturing, the company said Tuesday. The Gaithersburg, Maryland-based biotech has never brought a vaccine to market in its 33-year history. Its vaccine started early human testing in late-May and is set to produce results in July. Novavax didn't make any pledges on pricing or exclusive US future access to get the money, CEO Stanley Erck told Business Insider. "All this contract covers is a delivery of 100 million doses of vaccine," Erck said, with delivery starting in the fourth quarter of 2020 and finishing in the first quarter of 2021. Visit Business Insider's homepage for more stories . Novavax started this year in a precarious position. Entering its 33rd year in business, the company had racked up a deficit of $1.4 billion and had yet to bring any vaccines to market, putting it at risk of going bankrupt in 2020.
Novavax skyrockets after US government grants $1.6 billion for coronavirus vaccine creation
Novavax shares spiked as much as 38% early Tuesday after receiving $1.6 billion in coronavirus vaccine funding from the US government. The award is the largest yet from Operation Warp Speed, the White House's plan to rapidly develop and deliver a viable vaccine for the coronavirus pandemic. Part of the grant will fund a Phase 3 trial starting in the fall, according to a press release . Novavax also plans to use the award for delivering 100 million vaccine doses by the end of the year. Watch Novavax trade live here . Novavax stock surged as much as 38% in early Tuesday trading after the US government awarded $1.6 billion to fund the company's coronavirus vaccine trials and manufacturing. The grant is the largest yet to be paid out through "Operation Warp Speed," the Trump administration's plan to rapidly develop and deliver a coronavirus vaccine. Novavax aims to use some of the funding for a Phase 3 trial beginning in the fall. The award will also aid the firm in delivering 100 million doses by the end of the year, Novavax said in a press release . "We are grateful to the U.S. government for its confidence in our technology platform, and are working tirelessly to develop and produce a vaccine for this global health crisis," president and CEO Stanley Erck said.
Operation Warp Speed Awards Novavax $1.6 Billion For COVID Vaccine
Operation Warp Speed Awards Novavax $1.6 Billion For COVID Vaccine Tyler Durden Tue, 07/07/2020 - 08:16 With US equity futures under pressure on Tuesday morning - it's not surprising whatsoever that hopium-inspiring vaccine headlines are hitting the tape. Novavax was awarded $1.6 Billion in funding via Operation Warp Speed to support "large-scale manufacturing of NVX-COV2373." NOVAVAX ANNOUNCES $1.6 BILLION FUNDING FROM OPERATION WARP SPEED Gaithersburg, Maryland-based Novavax said in a statement that initial production of 100 million doses would start in late 2020. The aim is to have millions of doses ready by January 2021. NOVAVAX - OWS AWARD FUNDS LARGE-SCALE MANUFACTURING OF NVX-COV2373, INCLUDING PRODUCTION OF 100 MILLION DOSES STARTING IN LATE 2020 Novavax shares jumped as much as 35% in premarket Tuesday following the news. So far, this is the largest funding award via Operation Warp Speed, the White House program to fast track a vaccine for COVID-19. "What this Warp Speed award does is it pays for production of 100 million doses , which would be delivered starting in the fourth quarter of this year, and may be completed by January or February of next year," Novavax CEO Stanley Erck told Reuters .
Coronavirus vaccine: US govt awards Novavax $1.6 billion to cover testing, production
The announcement follows a $456 million investment in Johnson & Johnson's vaccine candidate in March, a $486 million award to Moderna Inc in April, and up to $1.2 billion in support in May for AstraZeneca's vaccine being developed with Oxford University
Johnson & Johnson cuts price of TB drug in poorer countries
NEW BRUNSWICK, New Jersey: Johnson & Johnson said on Monday (Jul 6) it was slashing the price of its version of tuberculosis drug bedaquiline to US$340 from US$400, for a six-month treatment, in low- and middle-income countries, to scale up its use during the COVID-19 pandemic. J&J's bedaquiline …
Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
GENEVA, July 6, 2020 /PRNewswire/ -- The Stop TB Partnership and Johnson & Johnson (NYSE: JNJ) – with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and middle-income…
JNJ Stock 1% Up in Pre-market, Johnson & Johnson's Legal Problems
On July 2, Johnson & Johnson stock closed at $140.97 per share. In the pre-market today, it is 1.15% up, $142.59 per share as of press moment.
Emergent to make drug substance for J&J's COVID-19 vaccine candidate | MarketScreener
Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate, in a deal valued at about… | July 6, 2020
Johnson and Johnson (JNJ) earnings preview: will increasing competition slow down the growth?
Johnson & Johnson (JNJ) is expected to report earnings on July 17 before market open. What are the JNJ earnings expectations? What news will the market be watching out for?
AbbVie (ABBV): Will The Stock Recover?
ABBV diverted the Rova-T program today—and that led to its stock price fall by 13%. When will the stock bounce back?
Follow Us